Study of the Role of Genetic Modifiers in Hemoglobinopathies
Public ClinicalTrials.gov record NCT05799118. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Study identification
- NCT ID
- NCT05799118
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 30,000 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 2 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2022
- Primary completion
- Sep 29, 2027
- Completion
- Sep 29, 2027
- Last update posted
- Mar 19, 2024
2022 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boston Children's Hospital | Boston | Massachusetts | 02115 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
Recently updated Hemoglobinopathies trials
Other public records listing Hemoglobinopathies. Sorted by last update posted; newest first. Not a recommendation.
- NCT05356195: Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) Active, not recruiting
- NCT05329649: Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) Active, not recruiting
- NCT07660783: Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases Not yet recruiting
- NCT07227155: The HOPE Biobank Resource (BMT CTN 2402 HOPE) Recruiting
- NCT04671212: Discarded Bone Marrow for Hematology Research Recruiting
- NCT01050855: Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05799118, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2024 · Synced Jul 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05799118 live on ClinicalTrials.gov.